Meprin β: A novel regulator of blood-brain barrier integrity

Markus Gindorf1, Steffen E Storck1, Anke Ohler1

  • 1Institute for Pathobiochemistry, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Insights

Meprin β (Mep1b) regulates blood-brain barrier (BBB) integrity by affecting tight junction proteins. Knocking out Mep1b strengthens the BBB, reducing permeability and brain water content.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Meprin β (Mep1b) is a metalloprotease involved in cleaving cell-adhesion molecules.
  • Mep1b dysregulation is linked to diseases characterized by barrier breakdown, including Alzheimer's disease and inflammatory bowel disease.

Purpose of the Study:

  • To investigate the role of Meprin β (Mep1b) in regulating tight junction (TJ) composition and blood-brain barrier (BBB) integrity in brain endothelium.

Main Methods:

  • Meprin β (Mep1b) overexpression in mouse brain endothelial cells (bEnd.3).
  • Analysis of global Mep1b knock-out (Mep1b-/-) mice and wild-type (wt) littermates.
  • Measurement of transendothelial electrical resistance (TEER) and paracellular permeability using [14C]-inulin.
  • Assessment of tight junction protein expression (claudin-5, occludin, ZO-1) in cerebral microvessels.
  • Quantification of IgG levels in cerebrospinal fluid (CSF) and brain water content.

Main Results:

  • Mep1b overexpression in bEnd.3 cells reduced claudin-5 expression, decreased TEER, and increased permeability.
  • Mep1b-/- mice exhibited increased expression of TJ proteins (claudin-5, occludin, ZO-1) in cerebral microvessels.
  • Primary brain endothelial cells from Mep1b-/- mice showed higher TEER compared to wt mice.
  • Mep1b-/- mice had lower IgG levels in CSF and reduced brain water content compared to wt mice.

Conclusions:

  • Meprin β (Mep1b) acts as a novel regulator of tight junction protein composition in brain endothelium.
  • Mep1b influences blood-brain barrier (BBB) tightness both in vitro and in vivo.
  • Targeting Mep1b may offer therapeutic strategies for conditions involving BBB dysfunction.